In conversation with...

Helen Frankish discusses articles on stroke prevention after TIA, and the potential of stem-cell therapy for the treatment of multiple sclerosis.

Helen Frankish discusses antipsychotics and Alzheimer's disease, and desmoteplase for ischaemic stroke.

Helen Frankish discusses articles about galantamine for severe Alzheimer's disease, and a genome-wide association study about CJD.

Helen Frankish discusses articles on NMDA-receptor encephalitis, perilesional brain oedema, and looks ahead to the TLN stroke conference in Beijing.

In this month's Lancet Neurology Podcast, Editor Helen Frankish discusses two research articles: one on the treatment of hemicrania continua, and another on perception of pain in a minimally conscious state. Also discussed is a review on sudden unexpected death in epilepsy.

Helen Frankish discusses highlights from the October issue, including follow-up results for trials comparing carotid stenting with endarterectomy in patients with stenosis; and the PRoFESS study comparing drug combinations to reduce the severity of recurrent ischaemic stroke.

Elena Becker-Barroso discusses highlights from the September issue, including the potential of PB2 to slow the development of amyloid beta in patients with Alzheimer's, and how telemedicine could improve stroke treatment.

Helen Frankish discusses biomarkers for indications of dementia, and other highlights from the August issue.

The International LRRK2 Consortium, which includes investigators in 21 centres, has collected data from almost 20000 patients with Parkinson's disease carrying mutations in the LRRK2 gene. The Lancet Neurology editor Elena Becker-Barroso and Daniel Healy, the corresponding author on their first report, summarises the findings and their implications in clinical practice in a podcast.

Editor Helen Frankish discusses highlights from the June issue: a randomised trial showing the efficacy of a ketogenic diet to protect against childhood epilepsy; and a trial with phase II results for the Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease.